Biogen strengthened the clinical case for BDCA2 as a therapeutic target in cutaneous lupus erythematosus after a second Phase II success for litifilimab (an investigational anti-BDCA2 therapy). The readout follows earlier efficacy in refractory patient groups, maintaining focus on BDCA2-driven targeting in a setting still largely treated with antimalarials and glucocorticoids. The latest result adds evidence that litifilimab could become the first targeted therapy for CLE, where unmet need remains high due to inadequate responses and dependence on repurposed immunomodulators. The update also positions Biogen to differentiate by indication and mechanism in autoimmune dermatology. If subsequent studies confirm the mid-stage signal, the program could shift standard-of-care discussions for difficult-to-treat skin-limited lupus manifestations.